Gossamer Bio Inc (NASDAQ:GOSS) shares saw strong trading volume on Friday . 2,403,564 shares changed hands during mid-day trading, an increase of 335% from the previous session’s volume of 552,849 shares.The stock last traded at $20.48 and had previously closed at $20.00.

A number of analysts recently weighed in on the stock. Evercore ISI assumed coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 price objective on the stock. Svb Leerink assumed coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 price objective on the stock. Leerink Swann assumed coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued an “outperform” rating on the stock. Barclays assumed coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued an “overweight” rating and a $27.00 price objective on the stock. Finally, Bank of America assumed coverage on shares of Gossamer Bio in a report on Tuesday, March 5th. They issued a “buy” rating and a $30.00 price objective on the stock. Five analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $29.25.

In related news, CFO Bryan Giraudo bought 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $96,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Russell J. Cox bought 7,200 shares of the firm’s stock in a transaction that occurred on Tuesday, February 12th. The stock was bought at an average price of $16.00 per share, with a total value of $115,200.00. The disclosure for this purchase can be found here. Insiders purchased a total of 14,750 shares of company stock valued at $236,000 in the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Marea Informative and is the property of of Marea Informative. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.mareainformativa.com/news/2019/03/17/gossamer-bio-goss-sees-unusually-high-trading-volume.html.

Gossamer Bio Company Profile (NASDAQ:GOSS)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Read More: Sell-Side Analysts

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.